CClinicalTrials.gg
WithdrawnNCT05527015ETS3Updated May 31, 2025

Bifocal Spectacles vs. Single Vision Spectacles for Esotropia Greater at Near

A Phase 3 interventional study of Bifocal Spectacles and Single Vision Lenses in Esotropia, sponsored by Jaeb Center for Health Research. Withdrawn. Open to participants aged 3 Years to 9 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Concerns over recruitment feasibility
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
3 Years to 9 Years
Sex
All
01

Study summary

Compare the proportion of BFL and SVL participants with treatment failure by 36 months, compare binocular function test scores between the BFL and SVL groups with both groups in BFL at 38 months after randomization (or 2 months after treatment failure), and evaluate treatment failure by 36 months according to baseline factor subgroups of: duration of constant esotropia pre-enrollment, presence of near stereoacuity on the Randot Preschool Stereoacuity test, in-office response of near alignment with +3.00 D lenses, and gradient AC/A ratio

Read the detailed description

Participants will be randomly assigned to treatment with a BFL or SVL spectacle correction for 3 years. Generally, participants will be followed at 3-month intervals for the first year and every 6 months thereafter until the primary outcome visit at 36 months. At each follow-up visit between 3 months and 36 months, ocular alignment and stereoacuity will be assessed to determine if any of the three study-specified failure criteria have been met (worsening of distance esotropia (ET), reduction in near stereoacuity, or frequent diplopia ("more than 2 times per day" over the last week). The primary outcome is failure at or before 36 months.

If a failure criterion is met between 3 to 30 months, participants randomized to SVLs will be prescribed BFLs and those in BFLs will be prescribed continued BFLs. Participants in both groups will return in BFLs 2 months after failure for a Post-failure Secondary Outcome Visit to determine the child's binocular function, after which the child will be released to treatment at investigator discretion. Participants with confirmed failure who complete the Post-failure Secondary Outcome Exam will return for the 12- and 24-month follow-up visits (abbreviated testing) as well as the 38-month Secondary Outcome Visit (they will not return for the 36-month Primary Outcome visit).

If a failure criterion is not met between 3 to 30 months, participants without confirmed failure will complete the 36-month Primary Outcome Visit, After the 36-month visit, SVL group participants will be prescribed BFLs and BFL participants will continue using BFLs.

All participants (i.e., regardless of failure status) will return for a 38-month Secondary Outcome Visit to assess binocular function.

02

Conditions studied

  • Esotropia

Browse trials for

Keywords

  • esotropia
  • bifocal
03

In context

Esotropia

33 studies on the registry are indexed under Esotropia; 10 are open to participants now.

Browse Esotropia studies →

Lead sponsor

Jaeb Center for Health Research is the lead sponsor of 126 studies on the registry; 17 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 3 to \<9 years
  • Esodeviation meeting all the following criteria is present in refractive correction (if required or worn)

    • Constant or intermittent esotropia ≥10∆ measurable by SPCT at near
    • Distance esotropia (constant, intermittent), esophoria, or orthophoria, with near esodeviation ≥10∆ larger than distance deviation by PACT

      • If constant ET at distance, then must be ≤6∆ by SPCT
      • If intermittent ET or esophoric at distance, can be any magnitude at distance (as long as near esodeviation is ≥10∆ larger than distance deviation by PACT)
  • Cycloplegic refraction within past 3 months (but not on day of exam)
  • Wearing spectacles for at least 4 weeks if refractive error is 0.75 D SE or more
  • Spectacles (if worn) must meet the following criteria:

    • SE refractive error must be corrected within ±0.625 D
    • Sphere power must be corrected within ±0.50 D
    • Anisometropia must be corrected within ±0.50 D SE
    • Cylinder power must be corrected within ±0.50 D
    • Cylinder axis must be within ±10 degrees if cylinder power is ≤1.00 D and within ±5 degrees if cylinder power is >1.00 D.
  • Best-corrected VA meeting the following criteria:

    • Better-seeing eye VA is age-normal (see section 2.2)
    • IOD in VA within 0.2 logMAR (although previous amblyopia is allowed)
    • Worse-seeing eye VA of 20/63 or better
  • Investigator and parent willing to forgo treatment of ET other than assigned randomized treatment for 36 months unless failure criteria are met.
  • Investigator willing to prescribe BFL-spectacles only (in both treatment groups) for 2 months after meeting failure criteria (if failed prior to 36 months); otherwise, between 36 and 38 months

Exclusion criteria

Exclusion Criteria:

  • Previous BFL wear (SVL spectacle wear of any duration is allowed)
  • Current or planned contact lens wear over the next 3 years
  • Myopic refractive error of more than -6.00 D SE
  • Previous strabismus surgery (including Botox injection), intraocular surgery (e.g., laser, anti-VEGF injection, or cataract), extraocular surgery (e.g., scleral buckle), or refractive surgery
  • Previous treatment for ET using miotics, VT, or prism within prior 3 months
  • Amblyopia treatment other than refractive correction within prior 3 months
  • Vertical deviation ≥3Δ at distance or near by PACT
  • Oculomotor findings consistent with infantile ET (e.g., latent nystagmus, manifest nystagmus, DVD)
  • AV pattern: ≥10∆ difference between upgaze and downgaze by PACT at distance
  • Paretic or restrictive strabismus
  • Constant exotropia at near when tested through the +3.00 D add (intermittent XT and exophoria are allowed)
  • Diplopia "more than 2 times per day" over the last week prior to enrollment by parental report. The frequency of diplopia, if any, must be "2 times or less per day" to be eligible.
  • Significant developmental delay that would interfere with child's ability to complete testing
  • Neurological conditions that could affect ocular motility (e.g., cerebral palsy, Down syndrome)
  • Immediate family member (child or sibling) of any site personnel directly affiliated with the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Single vision spectacles (SVLs)

    Device: Single Vision Lenses

  • Experimental
    Bifocal spectacles (BFLs)

    Device: Bifocal Spectacles

Interventions

  • DeviceBifocal Spectacles

    Bifocals with a +3.00 Diopter flat top 35

  • DeviceSingle Vision Lenses

    Single vision lens as prescribed by provider

06

What researchers measure

Primary outcomes

  1. Number of Participants meeting treatment failure at any follow up visit before 36 months

    Failure criteria can be described as 1. Distance motor failure: Constant ET ≥15∆ by simultaneous prism and cover test (SPCT) at distance. 2. Near stereo failure: Decrease in near stereoacuity on the Randot Preschool Stereotest of 2 or more levels from baseline or from 960" at baseline to nil (criteria not applicable if nil near stereo at baseline) 3. Binocular diplopia with a frequency of "more than 2 times per day" over the last week by parental report 4. Nonsurgical or surgical treatment for ET, other than the randomized treatment, is started before a failure criterion is met

    Time frame: 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

  • Study protocol · Jun 1, 2022
  • Informed consent form · Aug 4, 2022

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05527015
Lead sponsor
Jaeb Center for Health Research
Collaborators
National Eye Institute (NEI), Pediatric Eye Disease Investigator Group
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Sep 2025 (estimated)
Primary completion
Dec 2033 (estimated)
Completion
Feb 2034 (estimated)
Last update
May 31, 2025

Study contacts

Michael X Repka, MD, MBA
study chair · Wilmer Eye Institute, Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion